Sveriges Riksbank
| Bid date, 2021-03-18 | |
| Bid Date | 2021-03-18 |
| Bid times | 14.00-14.30 (CET/CEST) on the Bid date |
| Offered Amount | USD 10 billion |
| Maximum Permitted Volume of Bids | USD 4 billion from an individual institution |
| Settlement Date | 2021-03-22 |
| Minimum Permitted Bid Volume | 100 USD million per bid |
| Maximum Allocation | 40 per cent of the Offered amount |
| Allocation time | Not later than 15.00 (CET/CEST) on the Bid date |
| Maturity Date | 2021-06-14 |
| Maximum Number of Bids | 10 per individual institution |
| Minimum Bid Rate | 0.32 percentage points |
| Confirmation of bids to e-mail | eol@riksbank.se |
Stockholm, 2021-03-18
This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and the Swedish language version, the Swedish language version shall prevail. Complete terms and conditions can be retrieved at www.riksbank.se.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
FLSmidth A/S17.12.2025 07:10:00 CET | Press release
FLSmidth: Transactions under share buy-back programme
Sanofi Winthrop Industrie17.12.2025 07:00:00 CET | Press release
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysema
FLSmidth A/S17.12.2025 06:30:00 CET | Press release
FLSmidth & Co. A/S treasury shares exceeding 5% of share capital and voting rights
Bitget Limited17.12.2025 03:00:57 CET | Press release
Bitget Launches Gold, Forex and Commodities Markets for Crypto Users
DBV Technologies S.A.16.12.2025 22:05:00 CET | Press release
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
